Regulatory FDA approves Lilly obesity pill, triggering battle with Novo Nordisk BioPharma DiveFoundayo could erase the Wegovy pill s four-month head start as the two drugmakers clash on a debate of efficacy and convenience.RegulatoryMetabolic & GLP-1Read full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioPharma Dive Foundayo could erase the Wegovy pill s four-month head start as the two drugmakers clash on a debate of efficacy and convenience. RegulatoryMetabolic & GLP-1Read full story Post navigation Previous: Lilly bags FDA okay for Wegovy pill rival orforglipronNext: Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026